Home
Search results “Cancer therapy in drug delivary”
Nanoparticle drug delivery in cancer therapy
 
02:43
Nanobotmodels Company presents vision of modern drug delivery methods using DNA-origami nanoparticles. In animation you can see cancer therapy using doxorubicin, delivered by nanomedicine methods. You can watch detailed information about this animation on our webpage http://www.nanobotmedical.com/ Follow us on Facebook https://www.facebook.com/Nanobot.Medical.Animation/ Follow us on LinkedIN https://www.linkedin.com/company/nanobotmodels-medical-animation-studio/ Follow us on Twitter https://twitter.com/Nanobot_Studio Follow us on Instagram https://www.instagram.com/nanobot_medical_animation/ #medicine #health #biology #science #oncology #gene #chemistry #3danimation #medschool #pharmacy #pharmacology #education #molecule #cell #molecule #pharma #sciart #visualscience #sciart #ScientificCommunication #3D #Art #Animation #pharma #Medical #medicalanimation #medicalillustration #raredisease #cgi #patienteducation #Alzheimer #microbiology #lbrain #neuroscience #brain #nanotechnology #cell #microbiology #cells #lipid #nanobot #nanobotmedical #nanobotstudio #gastroenterology
Nanoparticle-based drug delivery in the fight against cancer
 
02:27
This animation describes the latest research developments in nanoparticle-based cancer therapies. It explores how the technology can be used to specifically target cancer cells over healthy cells and how scientists can exploit the natural processes of cells to deliver the drug inside the cell where it is needed for its cancer-killing effect. This animation was created by the 3D Visualisation Aesthetics Lab (UNSW, Sydney, Australia) as part of the research activities of the ARC Centre of Excellence in Bio-Nano Science and Technology. For more information please visit http://www.bionano.org.au/ To learn about other projects at 3DVAL, please visit https://www.artdesign.unsw.edu.au/3DVAL
Nanotechnology for Targeted Cancer Therapy
 
05:03
A short animation outlining the fundamentals of targeted nanomedicine for cancer therapy, one of our group's primary research focuses. For more information, see http://nanomedicine.uwaterloo.ca © 2010 University of Waterloo Frank Gu Research Group Waterloo Institute for Nanotechnology Department of Chemical Engineering
Views: 281478 FGRGAnimation
New Cancer Drug Shrinks All Tumors!?!
 
01:41
A new cancer treatment shrinks every kind of tumor it's been tested on. The Stanford Medical Center team has so far only tested the antibody on human cancer cells in petri dishes and in mice, but the results have been impressive: 10 out of the 10 tumors in mice shrank and in nine of the 10 mice, the cancer did not spread to their lymph nodes. Read the full story here: http://www.medicaldaily.com/articles/14434/20130328/cancer-treatment-cd47-miracle-bullet-breast-colon-bladder-antibody-eat-macrophage-immune.htm Subscribe to The Daily Conversation http://bit.ly/WZnLnd Join the conversation on Facebook http://www.facebook.com/thedailyconversation Add TDC to your circles on Google+ https://plus.google.com/100134925804523235350/posts Follow The Daily Conversation on Twitter http://www.twitter.com/thedailyconvo Videos used: Cancer Research UK http://www.youtube.com/watch?v=jWuyPi_nuJE normal mice.mpg http://www.youtube.com/watch?v=tcmyFj9DALI CD47 Antibody treatment shrinks or eliminates human cancer tumors in mice http://www.youtube.com/watch?v=EyGWZbmjeR0 3D Medical Animation - What is Cancer? http://www.youtube.com/watch?v=LEpTTolebqo Diabetes in Lab Mice Reversed with Natural Compound http://www.youtube.com/watch?v=0TlQWPg0NBk Images used: Petri dish http://www.flickr.com/photos/nathanreading/6751931965/lightbox/ Cell Culture http://www.flickr.com/photos/kaibara/3075268200/lightbox/ Mouse http://www.flickr.com/photos/dullhunk/7095792663/lightbox/ A new cancer-fighting drug has successfully shrunk every tumor its been tested on. This is a potentially huge breakthrough in the fight to cure cancer. The amazing work was done by a team at the Stanford University Medical Center that piggybacked on the knowledge that people with cancer have a lot more of these surface markers, called CD47, that say to the immune system, "don't eat me", essentially protecting bad cancer cells from being killed off. So they designed an antibody to shut these CD-47s up and introduced it into human cancer cells - not into humans directly yet, but in cells they took from humans and put in petri dishes and lab mice, and it worked: they found that when a variety of tumors, ranging from breast to brain, were hit with the antibody treatment, the CD47s were blocked, resulting in shrinking tumors, and a stopping of the spread of cancer. It worked in 10 out of the 10 mice they tested it on. This is so good, so groundbreaking, the team is now working with a $20 million grant to move from mouse trials to safety tests in humans. Now these results are maybe the most exciting ever in the history of cancer research, but there's still a ton of work to do. The microenvironment of a tumor interacting with the rest of the human body is way more complicated than treating a transplanted tumor in a mouse or one that's just lying in a petri dish. Tumors in humans could have additional immune suppressing effects that scientists will have to overcome and the antibody treatment used in this study could also create unknown side effects on the rest of the body. But that said, this story makes it seems like the fight to cure cancer is becoming more winnable by the day.
Views: 17247 The Daily Conversation
Improving Drug Delivery in Cancer Treatment
 
01:12
Northwestern chemistry professor Thomas O’Halloran discusses the use of “nanobins” — tiny lipid droplets that can house inorganic compounds like arsenic — in targeted cancer therapy.
Views: 92 NorthwesternU
New Personalized Drugs Hold Promise for Cancer Treatment
 
03:01
Tamer Shoeib, associate professor and chair of the Department of Chemistry, is conducting research that aims to create more targeted and personalized cancer drugs
Views: 618 AUC
Killing Cancer - New Brain Cancer Treatment Targets Tumors
 
04:46
Targeting brain tumors with enough anti-cancer medication is no easy task. But Stefan Bossmann and Deryl Troyer at Kansas State University are developing a novel materials treatment method for persons with brain cancer that uses a type of white blood cell to deliver anticancer drugs to particularly virulent brain tumors. Credits at end of video
Nanoparticles for Drug Delivery
 
02:22
Animation showing how nanoparticles can be used to delivery drugs
Views: 30299 Matt Miller
What are ‘targeted’ cancer drugs?
 
01:29
This video explains the concept of so-called 'targeted' cancer drugs, built from a fundamental undertanding of the shape and function of the faulty molecules inside cancer cells. Find out more about our work on cancer drugs here: http://bit.ly/1DfoCuq and read about how faults in the BRAF gene were linked to cancer by Cancer Research UK-funded scientists on our blog: http://bit.ly/1L77hbt
Views: 8942 Cancer Research UK
Targeting Mitochondria for Cancer Therapy - Dr  Sudipta Basu, IISER Pune
 
03:25
The short video describes how Dr. Sudipta Basu and his team of researchers from IISER Pune, used drug transporting Nanoparticles to target the Mitochondria (Power House of Cell) of Cancer Cells for Next-Generation Therapeutics. Production: Science Media Centre, IISER Pune Research and Script: Sudipta Basu, Abhik Mallick Crew: Vivek Kannadi, Parmeswar Singh Yadav Music: http://www.bensound.com Science Media Centre, IISER Pune: https://sites.google.com/acads.iiserpune.ac.in/smc/home IISER Pune has established the Science Media Centre to foster and strengthen science communication. We produce high quality media to communicate science through popular science films, research highlights and documentaries. The Science Media Centre conducts workshops to train personnel in print and electronic media to encourage science communication. We also archive science related events and activities of the institute.
Views: 1744 IISER Pune
Bringing a New Stem Cell Treatment to Cancer Patients: Dr. Karen Aboody, M.D. at TEDxAJU
 
17:17
Dr. Aboody is an Associate Professor both in the Department of Neurosciences and Division of Neurosurgery at City of Hope. Her research focuses on using stem cells to treat cancer, brain tumors in particular. She founded biotech company TheraBiologics, inc., which develops "cancer targeted drug delivery," to use entrepreneurship as a means by which to overcome the barriers to scientific progress. In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)
Views: 3470 TEDx Talks
When Nanobots Take on Cancer | Vikki Academy
 
02:21
Unbelievably, about half of cancer patients receive the wrong drug! A new technology which consists of nanobots now aims to change that. The nanobots allow the drug diagnostic stage to take place within the patient’s own body, rather than on a tissue culture in a lab. This leads to clinical recommendations based on the patient’s own body – personalized medicine. Watch and see how this epic battle takes place within our body.
Views: 16627 Vikki Academy
Cisplatin-bearing SPIONs for targeted drug delivery - Video abstract 63433
 
03:07
Video abstract of original research paper "Development and characterization of magnetic iron oxide nanoparticles with a cisplatin-bearing polymer coating for targeted drug delivery" published in the open access International Journal of Nanomedicine by Unterweger H, Tietze R, Janko C, et al. Abstract A highly selective and efficient cancer therapy can be achieved using magnetically directed superparamagnetic iron oxide nanoparticles (SPIONs) bearing a sufficient amount of the therapeutic agent. In this project, SPIONs with a dextran and cisplatin-bearing hyaluronic acid coating were successfully synthesized as a novel cisplatin drug delivery system. Transmission electron microscopy images as well as X-ray diffraction analysis showed that the individual magnetite particles were around 4.5 nm in size and monocrystalline. The small crystallite sizes led to the superparamagnetic behavior of the particles, which was exemplified in their magnetization curves, acquired using superconducting quantum interference device measurements. Hyaluronic acid was bound to the initially dextran-coated SPIONs by esterification. The resulting amide bond linkage was verified using Fourier transform infrared spectroscopy. The additional polymer layer increased the vehicle size from 22 nm to 56 nm, with a hyaluronic acid to dextran to magnetite weight ratio of 51:29:20. A maximum payload of 330 μg cisplatin/mL nanoparticle suspension was achieved, thus the particle size was further increased to around 77 nm with a zeta potential of -45 mV. No signs of particle precipitation were observed over a period of at least 8 weeks. Analysis of drug-release kinetics using the dialysis tube method revealed that these were driven by inverse ligand substitution and diffusion through the polymer shell as well as enzymatic degradation of hyaluronic acid. The biological activity of the particles was investigated in a nonadherent Jurkat cell line using flow cytometry. Further, cell viability and proliferation was examined in an adherent PC-3 cell line using xCELLigence analysis. Both tests demonstrated that particles without cisplatin were biocompatible with these cells, whereas particles with the drug induced apoptosis in a dose-dependent manner, with secondary necrosis after prolonged incubation. In conclusion, combination of dextran-coated SPIONs with hyaluronic acid and cisplatin represents a promising approach for magnetic drug targeting in the treatment of cancer. Read the Original Research paper here: http://www.dovepress.com/development-and-characterization-of-magnetic-iron-oxide-nanoparticles--peer-reviewed-article-IJN.
Views: 1895 Dove Medical Press
Nanomedicine drug delivery in cancer - Mark E. Davis - Na
 
10:30
Newest concept of drug dilevery system (nano prticles of drugs) for treatment of cancer.
Views: 6176 kulachi2011
Oncolytic Viruses to Cure Cancer? Health care, oncolytic virus research, future cancer therapy
 
22:35
More: http://www.virttu.com. How oncolytic viruses work to kill cancer cells in melanoma, head and neck, prostate cancer and glioblastoma brain timours. Replication of oncolytic viruses inside tumours. Pre-clinical trials. Phase I, Phase II and Phase III clinical trials on oncolytics. Use of oncolytic viruses to treat advanced malignant melanoma and mestatases -- Amgen research using an oncolytic virus developed from HSV (Herpes Simplex Virus). Oncolytic virus conference 2013. Problems with traditional chemotherapy -- side effects. Why Amgen bought an oncolytic viruse for $500m in cash and $500m to be paid if oncolytic trials are fully successful. Investor interest in oncolytic viruses. Oncolytic virus fund. Lessons from the history of research and development in monoclonal antibodies in cancer treatment. Why targeted cancer therapy -- a so-called "magic bullet" is so needed. How oncolytic viruses have been modified so that they cannot replicate in normal cells, but are still able to divide in a wide variety of human cancer cells. History of oncolytic viruses. Arming oncolytic viruses. Using viruses like Seprehvir (HSV-1716), adapted to carry an additional payload: extra genes which teach infected cancer cells to take up a compound containing radioactive iodine from the blood, delivering a micro-dose of radiation inside individual cancer calls. Or adding a gene which teaches cancer cells how to split a harmless pro-drug into two, inside the cell, releasing a very effective chemotherapy (alkylating agent). Targetting oncolytic viruses -- by adapting the feet of a virus to that they latch onto receptors on the surface of specific human cancer cells such as prostate (prostate antigens / PSA). Oncolytic virotherapy: Results of early Phase III Rheolysin clinical trials -- combined oncolytic virus and cancer chemotherapy. Side effects and safety profile of oncolytic viruses in clinical studies. Oncolytic virus Seprehvir has passed an FDA safety review with approval for systemic administration of oncolytic viruses to children with advanced cancer. How genes work in viruses, and how genetic engineering allows us to cut and paste genes from one species into another. Dr Video made by Patrick Dixon author of The Genetic Revolution, Chairman of Global Change Ltd, an advisor to many large pharma companies and Chairman of Virttu Biologics Ltd which owns the oncolytic virus Seprehvir (HSV-1716) and many other variants. Seprehvir has been shown to be highly effective against a wide range of cancers in pre-clinical studies. Seprehvir has been used in clinical trials with strong evidence of impact and almost negligible side effects - trials in glioblastoma (brain cancer), squamous cell carcinoma of head and neck and melanoma. Seprehvir is now being used in clinical trials for mesothelioma (lung cancer caused by asbestos), with others planned for hepatocellular carcinoma (live cancer) and ovarian cancer. OncoVEX GM-CSF developed by BioVex in phase III for advanced melanoma, could become first approved oncolytic virus in the western world. OncoVEX GM-CSF is also in a phase 3 trial for head and neck cancer. Reolysin (owned by Oncolytics Biotech) is in phase 3 clinical trials for head and neck cancer with early results in colorectal cancer. JX-594 is owned by Jennerex and in clinical trials for hepatocellular carcinoma. JX-594 is a thymidine kinase-deleted Vaccinia virus plus GM-CSF. NTX-010 is in clinical trials for small cell lung cancer and neuroblastoma. CGTG-102 (Ad5/3-D24-GMCSF) is owned by Oncos Therapeutics. GL-ONC1 is owned by Genelux in Phase I clinicla trials. Cavatak is being developed to treat malignant melanoma. Oncorine was approved a few years ago in China for treatment of head and neck cancer - built from H101 virus.
Liposomes: A Nobel Drug Delivery System
 
15:00
This video is a comprehensive and brief compilation about liposomes, its structure, history, and pros and cons of it. This video also summaries classification of liposome, its components and most important concepts of formation.
Views: 20828 devesh kumar jain
Targeting tumours: Challenges of antibody-drug conjugates
 
03:34
Treating cancer requires aggressive but targeted therapy. Some cancer drugs are too toxic because they damage healthy cells as well as tumor cells. So researchers are trying to develop ways to make sure drugs only target the right cells. One solution is to attach drugs to antibodies specific to a protein expressed on tumour cells. These drugs are called antibody-drug conjugates (ADCs). More than two dozen ADCs are currently being used in the clinic to treat diseases like Hodgkin's lymphoma and breast cancer, and researchers are developing many more. But it's taken decades to find the right combination of drug, antibody target and linker, and then make sure the right amount of ADC hits the tumor. In this 3D animation, produced by Nature Biotechnology, we hear about these challenges and the ways ADCs target cells. This content is editorially independent of sponsors. Animation by Nucleus Inc.. www.nucleuscatalog.com/home
Views: 22693 nature video
nanomedicine: nanotechnology for cancer treatment
 
02:26
Solving radiotherapy s biggest limitation. Medicine is now using physics every day to treat cancer patients. Nanotechnologies or Nanomedicine can help clinicians deliver safer and more efficient treatments by shifting the intended effect from the macroscopic to the subcellular level. www.nanobiotix.com www.laurentlevy.com
Views: 118238 Laurent L
Understanding Targeted Therapies for Cancer
 
44:22
Understanding Targeted Therapies for Cancer - National Institutes of Health 2009 - Publication Q026 - National Cancer Institute. Explains the three main types of targeted therapies, their risks and benefits, how they differ from conventional chemotherapy, which targeted therapies are currently approved by the Food and Drug Administration, and how one can find clinical trials that are evaluating these new treatment approaches. This animated tutorial is intended to help oncology health professionals become familiar with targeted therapies, so they can communicate with their patients about these new approaches and help them make better informed decisions about treatment.
Views: 31896 PublicResourceOrg
Nanoparticle-based drug delivery in the fight against cancer
 
02:32
This animation describes the latest research developments in nanoparticle-based cancer therapies. It explores how the technology can be used to specifically target cancer cells over healthy cells and how scientists can exploit the natural processes of cells to deliver the drug inside the cell where it is needed for its cancer-killing effect. This animation was created by the 3D Visualisation Aesthetics Lab (UNSW, Sydney, Australia) as part of the research activities of the ARC Centre of Excellence in Bio-Nano Science and Technology. For more information please visit http://www.bionano.org.au/ To learn about other projects at 3DVAL, please visit https://www.artdesign.unsw.edu.au/3DVAL
Targeted Therapy for Liver Cancer Assisted by Nanotechnology | Taeghwan Hyeon | TEDxKFAS
 
15:03
Due to the limited effect of existing drugs, liver cancer has one of the worst prognoses for survival, and being diagnosed with it is essentially a death sentence. Nanoparticle synthesis expert Dr. Taeghwan Hyeon explains that by using the nanoparticle form of triptolide with a grenade and missile function, we can treat liver cancer more effectively. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://tedxkfas.com Dr. Taeghwan Hyeon is Professor/SNU Distinguished Fellow at the Chemical and Biological Engineering of Seoul National University (SNU), and also Director of Center for Nanoparticle Research of Institute for Basic Science (IBS). For the last 17 years, he has been working on the synthesis and medical applications of uniform-sized nanoparticles at SNU, and was selected as one of the top 100 chemists by UNESCO&IUPAC in 2011. Since 2010, he has served as an Associate Editor of Journal of the American Chemical Society. He is a Fellow of the Royal Society of Chemistry (RSC) and the Materials Research Society (MRS). He received many awards including the Hoam Prize (2012, Samsung Hoam Foundation) and the POSCO-T. J. Park Award (2008). This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Views: 2393 TEDx Talks
Going nano for better cancer treatments
 
02:33
UAlberta professor Afsaneh Lavasanifar uses nanotechnology to target medicine delivery and improve drug absorption. Primarily focused on chemotherapy drugs, which can be harmful to organs like the heart and kidneys, she's developed a patented polymer technology that can carry medicines to targeted areas—delivering medicine directly to a tumour and away from surrounding healthy tissues. The result—better, more effective medicine with less side-effects.
Views: 963 UniversityofAlberta
Cancer cure: Promising new gene therapy drug reprograms immune cells to kill cancer - TomoNews
 
08:16
SILVER SPRING, MARYLAND— A panel of experts advising the U.S. Food and Drug Administration has unanimously recommended the approval of a new cancer drug from pharmaceutical giant Novartis. The drug would be used to treat people suffering from leukemia. The New York Times reports that tisagenlecleucel is a gene therapy drug used to treat a blood cancer known as B-cell acute lymphoblastic leukemia in patients aged 3 to 25. The drug uses chimeric antigen receptor T-cell therapy, which reprograms immune cells to defeat cancer. The treatment first extracts a patient's own T-cells, then genetically modifies them using tisagenlecleucel to grow new receptors. These receptors target CD19, a protein expressed by malignant B-cells. Copies of the new cells are grown in the lab by the millions and injected back into the patient, where they then attack the cancer cells. In one test, the treatment led to complete remission in 83% of 52 patients. But it has potentially deadly short-term side effects, such as high fevers, low blood pressure, and lung problems. It's unclear what the long-term side effects are, if any. Therefore, patients who received treatment are recommended to be monitored for 15 years. The FDA will likely decide whether or not to approve the Novartis drug in the next few months. If they do, it will be the first gene therapy drug of its kind to hit the U.S. market. ----------------------------------------­--------------------- Go to https://www.patreon.com/tomonews and become a Patron now TomoNews is now on Patreon and we've got some cool perks for our hardcore fans. TomoNews is your best source for real news. We cover the funniest, craziest and most talked-about stories on the internet. Our tone is irreverent and unapologetic. If you’re laughing, we’re laughing. If you’re outraged, we’re outraged. We tell it like it is. And because we can animate stories, TomoNews brings you news like you’ve never seen before. Visit our official website for all the latest, uncensored videos: http://us.tomonews.com Check out our Android app: http://bit.ly/1rddhCj Check out our iOS app: http://bit.ly/1gO3z1f Get top stories delivered to your inbox everyday: http://bit.ly/tomo-newsletter See a story that should be animated? Tell us about it! Suggest a story here: http://bit.ly/suggest-tomonews Stay connected with us here: Facebook http://www.facebook.com/TomoNewsUS Twitter @tomonewsus http://www.twitter.com/TomoNewsUS Google+ http://plus.google.com/+TomoNewsUS/ Instagram @tomonewsus http://instagram.com/tomonewsus -~-~~-~~~-~~-~- Please watch: "Crying dog breaks the internet’s heart — but this sad dog story has a happy ending" https://www.youtube.com/watch?v=4prKTN9bYQc -~-~~-~~~-~~-~-
Views: 10573 TomoNews US
Convection enhanced delivery of chemotherapy to paediatric brain stem tumours
 
11:28
Prof Gill talks to ecancertv at Children with Cancer UK’s workshop on Drug Delivery in Paediatric Brain Tumours in London, UK. In the interview he discusses early clinical experience of intermittently delivering carboplatin directly to paediatric brainstem tumours using a novel implantable neurosurgical device. The device consists of four very fine catheters that are implanted deep within the brain using a dedicated robotic technique. Chemotherapeutic drugs can then be injected directly into the site the tumour via a technique called convection enhanced delivery (CED). The device was originally developed for delivering a protein therapy to adults with Parkinson’s disease and is now being tested in children with diffuse intrinsic pontine glioma (DIPG), a tumour that is not amenable to surgical resection.
Views: 2325 ecancer
NanoMedicine Cancer Drug Delivery
 
02:24
Medicines do not simply enter the body and wander around until they finds something to cure, and getting compounds to their intended target is one of the biggest challenges for drug manufacturers. The virtual lab in NanoMission V2 allows you to go from the organ view down to individual cells, analyzing the cells compositions, traveling down the blood stream and seeing the medicine you've created in action.
Views: 10651 PlayGen Ltd
Cancer and Drug Delivery - Targeted Drug-carrying Phage Nanomedicines
 
08:44
Lecturer: Prof. Itai Benhar, Faculty of Life Sciences, TAU "From Discovery to Products: Innovative Technologies from Tel Aviv University" An event that was held at the Tel Aviv University, 28/5/08
Views: 1112 TAUVOD
Invention 8 - DJK - Gold Nanoparticle Cancer-Drug Delivery System
 
01:26
https://www.youtube.com/playlist?list=PLvu6n-GsGFsYNp-TFHeYOrB_bpaYYrjHM NanoGuard Pharmaceuticals (NG) introduces a gold nanoparticle-based anti-cancer drug delivery system for clinicians and researchers to combat hard-to-reach and inoperable cancers. Nano-sized structured, our product reaches cancers with enhanced accumulation and causes heat-related tumor ablation via infrared excitation. Non-toxic, it can differentiate tumors from normal tissues even 48-hours post-injection. The technology is owned by National Institute of Biomedical Imaging and Bioengineering. Currently the product faces competition from liposomes, polymers, gels, and sprays which all can exhibit similar functions of delivering anti-drug medicine. Around 15% of market specializes in nanoparticle-based delivery system. Thus, the market is considered very competitive. However, the product has competitive advantages as a versatile cancer treatment method with unparalleled specifications. The overall market for cancer treatment is expected to value at USD 80 Billion with sustained double-digit growth rate. It is believed that penetrating into developed countries such as the US and EU, where the demand for high-end cancer treatment is high, can yield a tremendous return. Meanwhile, these regions have strict patent protection, ensuring NG’s competitive advantage over 20 years. The product is currently at medical phase 0. R&D of additional 10-15 years with investment amounted to USD $1.5 billion is expected before launching. Once the product is clinically usable, NG will market the product to hospitals and treatment centers to sell off the solution priced at a medium level. NG only collects payment monthly based on the quantity the agents have sold out during that period, allowing NG to capture market share steadily by shifting the inventory risk away from the agents. Ideally, such a business model would generate USD 750 Mn revenue in the first year with CAGR at 20% in next 10 years and finally stabilizes at USD 4.6 Bn annually for additional 10 years at 30% margin. Considering burn rate of 200 million annually for 10 years, the IRR is 15%. However, the actual IRR may range from 10-20%. The Management Team of NG now constitutes of two postgraduate professionals in charge of technical solutions, three medical advisors with strong soft skills for pitching plus two business-side marketing and finance experts.
Views: 2764 LagtronicsURT
NanoMedicine Cancer Drug Delivery
 
02:21
NanoMission - NanoMedicine Module : Take control as a biomedical scientist! Help to cure cancer through observation and experimentation by building nanoscopic particles and measuring their effects on the patient at the cellular level. Visit http://www.nanomission.org to Download the game!
Views: 27174 PlayGen Ltd
Creating a "Living Drug" to Fight Cancer
 
02:57
Recently a Food and Drug Administration panel unanimously recommended the agency approve a cutting-edge cancer therapy. One expert called it the “most exciting thing I’ve seen in my lifetime.” So what is it? CAR T-cell treatment is a process where millions of a patient’s T-cells are removed and genetically engineered. These new T-cells capable of killing thousands of cancer cells, and a single turbocharged cell can destroy up to 100,000 cells.
Views: 346 The Spoke
Invention 1 - MCW-GX- Redefining Precision Delivery in Cancer
 
02:01
(https://www.youtube.com/playlist?list=PLvu6n-GsGFsYNp-TFHeYOrB_bpaYYrjHM NanoRed Therapeutics Redefining Precision Delivery in Cancer Many promising cancer therapies fail to benefit patients because of the toxicity from systemic administration. NanoRed’s technology overcomes this problem by enabling site-specific delivery of chemotherapy, immunotherapy, and other anti-tumor therapies, granting the physician precise control of treatment. NanoRed’s therapy treats tumors and engages the immune system to eliminate residual disease while sparing the patient from severe toxicities that are common with current treatments. Childhood rhabdomyosarcoma (RMS) is an Orphan Disease, which urgently requires new therapies. NanoRed’s drug, an infrared activated chemotherapeutic liposome solves the core problems associated with standard therapies. After proof-of-concept in RMS, NanoRed’s technology will be applied to other cancers, as a “one pathway-many diseases” paradigm. Our Solution NanoRed’s infrared activated liposomes will be administered to patients intravenously. Liposomes contain IL-12, a potent immunostimulant, which is toxic when given systemically. Illumination with infrared allows physicians to specifically release IL-12 immunotherapy directly into the tumor, avoiding systemic toxicities. Activated liposomes also contain HPPH, which upon illumination can directly kill tumor cells, generating a pro-immunogenic environment. This dual action therapy generates a long lasting, anti-tumor immune response to eliminate residual disease. The end result is a more effective, less toxic therapy. Development Pathway We project that $1.2M will fund preclinical work, while $8M will fund a Phase I clinical trial. NanoRed will pursue funding sources such as Small Business Innovation Research (SBIR) grants and will leverage NCI resources to accelerate development. Out-licensing the initial clinical program after achieving clinical proof of concept delivers value to investors and accelerates the roll out of our therapy in RMS and other malignancies. Targeted therapies are in demand, generating licensing deals worth $334M (median deal) in upfront and milestone payments (Thompson Reuters). Management Team NanoRed’s team is composed of experienced biotech industry veterans, chemists, immunologists, pharmacologists, toxicologists and entrepreneurs with 23 years of cumulative experience. The team is advised by industry leaders from the pharmaceutical, biotech and investment sectors. NanoRed’s vision is to harness a new, precise delivery platform to bring next generation cancer therapies that are less toxic and more effective to patie Music: www.bensound.com and http://www.purple-planet.com Logo and animation produced by studio OY
Views: 821 Gang Xin
Micromotor-enabled active drug delivery for in vivo treatment of stomach infection
 
01:46
Video from a study published in Nature Communications titled "Micromotor-enabled active drug delivery for in vivo treatment of stomach infection." It demonstrates the first attempt to apply Mg-based micromotors, loaded with antibiotic drug clarithromycin (CLR), for in vivo treatment of H. pylori infection in a mouse model. Link to study: https://www.nature.com/articles/s41467-017-00309-w#Sec2 Authors: Berta Esteban-Fernández de Ávila, Pavimol Angsantikul, Jinxing Li, Miguel Angel Lopez-Ramirez, Doris E. Ramírez-Herrera, Soracha Thamphiwatana, Chuanrui Chen, Jorge Delezuk, Richard Samakapiruk, Valentin Ramez, Liangfang Zhang & Joseph Wang
Views: 1731 Teodora Zareva
Therapeutic Nanoparticles for Drug Delivery in Cancer
 
02:00
Edited by CienciAdictos. Sources: - Video: http://www.youtube.com/watch?v=emEua2eJp1U - Audio: https://soundcloud.com/sortedfood/marshmallows-soundtrack
Views: 1155 CienciAdictos
How can graphene be used for cancer treatment?
 
00:49
Graphene's high surface area allows us to load even more drugs onto the surface of graphene than current materials used. This will help with the development of cancer treatment, helping to reduce the effects of more invasive cancer treatments. Graphene could help drugs to move quickly through the body and be able to attack cancer cells more effectively. Narrated by Dr Ania Servant Find out more at http://www.graphene.manchester.ac.uk Twitter https://twitter.com/UoMGraphene Facebook https://www.facebook.com/UoMGraphene Google+ https://plus.google.com/118335438365412011325/videos
FCSC - OncopHore Nanotechnologies – Elevator Pitch
 
02:07
Conventional drug delivery of cancer therapeutics suffers from several limitations. Moreover, the most recently developed anti-cancer agents possess poor water solubility resulting in sub-optimal drug delivery to the tumor. Nanotechnology based drug delivery systems ensure targeted delivery of a therapeutic agent while reducing the required dose and side effects of conventional drug therapies. With fewer anti-cancer drugs in pipelines and a high FDA rejection rate, there is a high demand for nanoparticle drug delivery systems to reignite interest in formally rejected chemotherapeutics. Reformulating discontinued anticancer agents using nanoparticles can significantly improve the sensitivity and efficacy of these compounds and will help pharmaceutical companies gain marketing exclusivity and patent protection. OncopHore Nanotechnologies offers a unique nanoparticle designed by a physicist at the University of Pennsylvania and covered by a patent. This nanoparticle relies on the physicochemical properties of the coated peptides to selectively target cancerous cells. The increased metabolic activity of cancer cells contributes to tumor acidosis. Our nanoparticle is a 20 nm, biocompatible particle, coated with low molecular weight peptides (17-amino acid.) This particle facilitates the packaging of lipophilic or unstable drugs or genes, protecting them from degradation in plasma. The nanoparticle takes advantage of the slightly acidic pH (6.5-7.0) surrounding cancer cells to deliver the drug within the vicinity of cancer cells. Currently approved nanoparticle-based drug delivery vehicles such as liposomes, polymerosomes, and PEGylated nanoparticles require internalization, releasing the drug cargo intracellularly. Moreover, other pH-triggered nanoparticles currently being studied are comparatively larger in size (~80 nm) and require a 100-fold change in pH which only occurs intracellularly. The disadvantages of these targeted nanoparticles include 1) high manufacturing cost 2) immune related toxicity 3) degradation of drugs by intracellular enzymes and 3) inefficiency due to varied tumor complexity. Thus, our ultra pH-sensitive nanoparticle will not only help reduce the drug dosage and toxicity while increasing potency of cancer treatments, but will also render increased tumor penetration with dense stroma. The global market for nanotechnology drug delivery systems is projected to increase to $45 billion by 2019, with CAGR of 23% for the period of 2014 to 2019. Oncophore Nanotechnologies will dominate over 25% of this market after launching this nanoparticle. We are based in Philadelphia, PA, with core founding members from the Children’s Hospital of Pennsylvania and the University of Pennsylvania with diverse expertise in scientific research. Our team of world-class scientists and business experts are ready to change the way drugs are delivered and improve cancer management for millions of people.
Views: 150 Margalit Haber
How Exosomes Target Tumor Cells ‐ Lessons Learned from Nature
 
17:54
Speaker: Dr. Silke Krol, Fondazione IRCCS Istituto Neurologico "Carlo Besta" IFOM‐IEO‐campus, Milan (I) "Novel Approaches for Therapeutic Intervention and Drug Delivery " Chair Prof. Dr. Jan Mollenhauer, University of Southern Denmark, Head Molecular Oncology, Odense (DK) Day 1 Hall Montreal CLINAM 2015 The European Summit for Clinical Nanomedicine and Targeted Medicine – The Translation to Knowledge Based Medicine Eighth Conference and Exhibition, June 29 2015
Views: 1225 TAUVOD
Polymeric nanoparticles for targeted oncotherapy – Video abstract 56932
 
02:28
Video abstract of a review paper "Polymeric nanoparticles for targeted treatment in oncology: current insights" published in the open access International Journal of Nanomedicine by Prabhu RH, Patravale VB, Joshi MD. Abstract: Chemotherapy, a major strategy for cancer treatment, lacks the specificity to localize the cancer therapeutics in the tumor site, thereby affecting normal healthy tissues and advocating toxic adverse effects. Nanotechnological intervention has greatly revolutionized the therapy of cancer by surmounting the current limitations in conventional chemotherapy, which include undesirable biodistribution, cancer cell drug resistance, and severe systemic side effects. Nanoparticles (NPs) achieve preferential accumulation in the tumor site by virtue of their passive and ligand-based targeting mechanisms. Polymer-based nanomedicine, an arena that entails the use of polymeric NPs, polymer micelles, dendrimers, polymersomes, polyplexes, polymer–lipid hybrid systems, and polymer–drug/protein conjugates for improvement in efficacy of cancer therapeutics, has been widely explored. The broad scope for chemically modifying the polymer into desired construct makes it a versatile delivery system. Several polymer-based therapeutic NPs have been approved for clinical use. This review provides an insight into the advances in polymer-based targeted nanocarriers with focus on therapeutic aspects in the field of oncology. The full paper is available at: http://www.dovepress.com/polymeric-nanoparticles-for-targeted-treatment-in-oncology-current-ins-peer-reviewed-article-IJN
Views: 1078 Dove Medical Press
Penetration Enhancers for better Effectiveness of Intra‐Tumoral Anti‐Cancer Drug Delivery Systems
 
13:18
Hen Popilski, M. MedSc Student, Department of Clinical Biochemistry and Pharmacology Ben‐Gurion University of the Negev, Beer‐Sheva (IL) 26. Nanodrug Delivery: Novel Insights and Strategies CLINAM 2016 - day 2 Hall Rio 28.6.16
Views: 265 TAUVOD
Philips localized drug delivery development - Sonodrugs
 
00:15
Philips is leading a major new European project to develop drug delivery technologies that could significantly impact the treatment of cancer and cardiovascular disease. By allowing drugs to be delivered to disease sites via the patients bloodstream and then activated by focused ultrasound pulses, the SonoDrugs project aims to maximize the therapeutic efficiency and minimize the side effects of drug treatments for cancer and cardiovascular disease. The project, which involves a total of fifteen industrial partners, university medical centers and academic institutions from throughout the European Union (EU), will run for four years and has a budget of €15.9 million, €10.9 million of which is being funded under the EUs 7th Framework program.
Views: 1671 philipsnetherlands
Molecular Oncology: Past, Present and Future of Anti-Cancer Drug Design
 
01:34:07
The discovery of effective anti-cancer drugs represents one of the greatest challenges to face humanity. Whilst great progress has been made in both our understanding and our ability to discover new treatments, significant challenges remain. Dr Michael J. Waring described the role medicinal chemistry has played in the development of today's established treatments, modern approaches to targeted therapies and future challenges in tackling resistance to these therapies. This was showcased with stories of how some of today's recognised drugs were discovered and how modern medicinal chemistry approaches have been applied to discover new treatments, which show great promise for the future. This was the inaugural RSC Biological and Medicinal Chemistry Sector Lectureship.
Cancer drugs with nanoparticles gives more effect and fewer side effects
 
01:21
Only a small proportion of cancer drugs are injected into the cancerous tumor cells today. Nanoparticles will ensure that the drugs reach all the way into the cancer tumour before dissolving in the body, causing limited side effects.
Views: 31 NACAMED
New blood-cancer treatment: new drug which may alleviate chemotherapy side effects
 
01:05
Check out our official website: http://us.tomonews.net/ Check out our Android app: http://goo.gl/PtT6VD Check out our iOS app: http://bit.ly/1gO3z1f ----------------------------------------­----------------------------------------­---------------- A new blood cancer drug, a potential alternative to the common chemotherapy drug melphalan but with fewer side effects, has passed a crucial mid-stage trial, according to a Reuters report. The new drug Captisol-enabled melphalan developed by the U.S.-based Spectrum Pharmaceutical does not contain propylene glycol, a chemical believed to be responsible for the side effects of chemotherapy, such as renal and cardiac failure. The injectable drug is now being tested in patients with multiple myeloma undergoing stem cell transplants. Multiple myeloma is a form of blood cancer caused by the proliferation of cancerous plasma cells. As such malignant cells multiply, the normal blood cells will be crowded out. Around 22,000 cases of multiple myeloma are diagnosed in the United States each year. ----------------------------------------­----------------------------------------­---------------- Welcome to TomoNews, where we animate the most entertaining news on the internets. Come here for an animated look at viral headlines, US news, celebrity gossip, salacious scandals, dumb criminals and much more! Subscribe now for daily news animations that will knock your socks off. Check out our Android app: https://play.google.com/store/apps/details?id=com.nextmedia.gan Check out our iOS app: https://itunes.apple.com/app/tomonews/id633875353 For news that's fun and never boring, visit our channel: https://www.youtube.com/user/TomoNewsUS Subscribe to stay updated on all the top stories: https://www.youtube.com/channel/UCt-WqkTyKK1_70U4bb4k4lQ?sub_confirmation=1 Stay connected with us here: Facebook http://www.facebook.com/TomoNewsUS Twitter @tomonewsus http://www.twitter.com/TomoNewsUS Google+ http://plus.google.com/+TomoNewsUS/ Instagram @tomonewsus http://instagram.com/tomonewsus -~-~~-~~~-~~-~- Please watch: "Crying dog breaks the internet’s heart — but this sad dog story has a happy ending" https://www.youtube.com/watch?v=4prKTN9bYQc -~-~~-~~~-~~-~-
Views: 18021 TomoNews US